Loading
A phase 3 trial of Flumatinib in Leukaemia, run by Zhongda Hospital, with a status the registry has not verified recently.
Study of Efficacy and Safety of Flumatinib Combined With Chemotherapy in Ph Positive ALL is a phase 3 interventional study registered as NCT04375683 by Zhongda Hospital, with 28 participants planned, started 2020-03-01 and due to reach its primary completion in 2022-12-30. Interventions recorded: Flumatinib. Conditions recorded: Acute Lymphocytic Leukemia, Adult B-Cell, BCR-ABL1 Fusion Protein Expression.
Linked to the drug Flumatinib because the registry names it among its interventions and Leukaemia among its conditions. Registry record only: no result has been read by an editor.
Shares Flumatinib, Leukaemia (all types) and the tag pipeline.
Shares Flumatinib, Leukaemia (all types) and the tag pipeline.
Shares Leukaemia (all types) and the tag pipeline.
Shares Leukaemia (all types) and the tag pipeline.
Shares Leukaemia (all types) and the tag pipeline.
Shares Leukaemia (all types) and the tag pipeline.
Shares Leukaemia (all types) and the tag pipeline.
Shares Leukaemia (all types) and the tag pipeline.